Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03ZFX
|
||||
| Former ID |
DNC013564
|
||||
| Drug Name |
D-254C
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [529287] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H32N2O
|
||||
| Canonical SMILES |
C1CC(NCC1NCC(CC2=CC=CC=C2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
|
||||
| InChI |
1S/C27H32N2O/c30-25(18-21-10-4-1-5-11-21)20-28-24-16-17-26(29-19-24)27(22-12-6-2-7-13-22)23-14-8-3-9-15-23/h1-15,24-30H,16-20H2/t24-,25+,26-/m0/s1
|
||||
| InChIKey |
YKFRXVGLZNKBAS-NXCFDTQHSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent dopamine transporter | Target Info | Inhibitor | [529287] | |
| Sodium-dependent noradrenaline transporter | Target Info | Inhibitor | [529287] | ||
| Sodium-dependent serotonin transporter | Target Info | Inhibitor | [529287] | ||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
| Parkinson disease | |||||
| Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesisP04373:5HT1 type receptor mediated signaling pathway | |||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Dopaminergic Neurogenesis | |||||
| Parkinsons Disease Pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport | |||||
| SIDS Susceptibility Pathways | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| Ref 529287 | Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. Epub 2008 Jan 11.Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: interaction with dopamine, serotonin, and norepinephrine transporters. | ||||
| Ref 529287 | Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. Epub 2008 Jan 11.Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: interaction with dopamine, serotonin, and norepinephrine transporters. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.